TLDR
- VEEV shares climbed approximately 12% following a quarterly earnings surprise, posting EPS of $2.06 versus analyst expectations of $1.94.
- Quarterly revenue reached $836 million, marking a 16% increase from the prior year and surpassing the $811 million projection.
- First-quarter outlook calls for $2.13–$2.14 EPS alongside $855–$858 million in revenue, exceeding analyst forecasts.
- The company expects fiscal 2027 revenue between $3.585–$3.6 billion, higher than the $3.56 billion consensus estimate.
- Half of the world’s top 20 biopharmaceutical firms have now adopted its Vault CRM solution.
Veeva Systems entered 2026 on shaky ground, with shares declining 16% before its quarterly report. Wednesday evening’s announcement reversed that trend dramatically.
The fourth-quarter performance exceeded analyst projections across key metrics. Adjusted earnings per share hit $2.06, outpacing the $1.94 consensus figure. Top-line growth accelerated 16% compared to last year, reaching $836 million versus expectations of $811 million.
Investors reacted swiftly. Shares of VEEV jumped roughly 12% during Thursday’s opening session.
The positive momentum extended beyond historical performance. Management’s forward-looking statements provided additional confidence to market participants.
Looking ahead to the first quarter, the company forecast earnings per share ranging from $2.13 to $2.14, surpassing the Street’s $2.10 projection. The revenue outlook of $855 to $858 million similarly exceeded the $853 million analyst estimate.
For the complete fiscal year 2027, management anticipates revenue between $3.585 and $3.6 billion. This guidance surpasses the consensus target of $3.56 billion. The non-GAAP EPS forecast of $8.85 also beats the $8.60 expectation.
The billings forecast captured significant analyst interest. KeyBanc’s Scott Schoenhaus highlighted the “healthy billings guidance” as a supportive factor for the stock’s valuation amid widespread selling pressure affecting software companies.
Schoenhaus, maintaining a Sector Weight rating on VEEV, suggested the results should alleviate worries surrounding the broader software industry downturn linked to emerging AI coding technologies.
The CRM Commitment
One metric from the earnings report deserves special attention. Veeva revealed that half of the top 20 global biopharmaceutical companies have now adopted its Vault CRM platform.
This represents tangible evidence of acceleration in a critical product segment.
Vault CRM serves the unique needs of life sciences organizations, managing regulatory compliance and operational processes that generic CRM solutions inadequately address. Securing major pharmaceutical clients requires extensive effort — making these commitments particularly significant.
Veeva’s financial metrics support the expansion narrative. The firm maintains a net profit margin of 27.93% alongside a gross margin of 75.67%. Its current ratio stands at 7.53 while the debt-to-equity ratio registers at just 0.01.
These figures demonstrate exceptional balance sheet strength.
Valuation Check
Prior to the post-earnings surge, VEEV’s price-to-earnings multiple of 36.67 hovered near its decade-low point. The price-to-sales ratio of 10.25 and price-to-book ratio of 4.4 similarly approached multi-year minimums.
Wall Street’s consensus price target of $292.17 stood significantly above the pre-earnings trading level.
Institutional investors control 86.51% of outstanding shares, signaling substantial confidence from major asset managers. Company insiders hold 7.59%, with insider transactions showing 1,000 shares sold over the previous three months.
The firm’s three-year revenue compound annual growth rate measures 13.4%, while its Altman Z-Score of 19.88 indicates robust financial stability.
By Thursday morning, VEEV changed hands near $201.33, representing a significant advance from the approximately $188 level before the quarterly disclosure.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
